share_log

Bio-Rad Maintains Its FY24 Financial Outlook

Bio-Rad Maintains Its FY24 Financial Outlook

Bio-Rad 维持其 24 财年财务展望
Benzinga ·  05/07 16:24

The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent.

该公司继续预计,非公认会计准则、货币中立的收入将增长约1.0%至2.5%,预计非公认会计准则营业利润率约为13.5%至14.0%。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发